Home Newsfeeds RBC Capital Downgrades Mosaic to Sector Perform, Lowers Price Target to $65

RBC Capital Downgrades Mosaic to Sector Perform, Lowers Price Target to $65

RBC Capital analyst Andrew Wong downgrades Mosaic (NYSE:MOS) from Outperform to Sector Perform and lowers the price target from $85 to $65.

byBenzinga Newsdesk

October 3, 2022

1 minute read

RBC Capital analyst Andrew Wong downgrades Mosaic (NYSE:MOS) from Outperform to Sector Perform and lowers the price target from $85 to $65.

Tesla, Shopify, Roku, Twilio, Quantumscape: Why These 5 Stocks Are Drawing Investors’ Attention Today

By Bhavik Nair

February 15, 8:57 PM

Major Wall Street indices closed in the green on Wednesday despite an initial dip following the release of…

Gold Resource Q4 EPS $(0.07) Misses $0.03 Estimate, Sales $29.03M Miss $29.44M Estimate

By Michael Horton

March 2, 6:53 PM

Gold Resource (AMEX:GORO) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $0.03 by 333.33 percent. This is a 333.33 percent decrease over earnings of $0.03 per share from the

GORO

Why Is Pain & Liver Disease Focused DURECT Stock Plunging Today?

By Vandana Singh

November 8, 12:38 PM

DURECT Corporation (NASDAQ: DRRX) released topline

DRRX

Coherus BioSciences Acquires Small Immuno-Oncology Player Surface Oncology For $40M

By Vandana Singh

June 16, 8:00 AM

Coherus BioSciences Inc (NASDAQ: CHRS) has agreed to acquire Surface Oncology Inc (NASDAQ: SURF), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that

CHRS

RBC Capital Downgrades Mosaic to Sector Perform, Lowers Price Target to $65

Related Posts

Tesla, Shopify, Roku, Twilio, Quantumscape: Why These 5 Stocks Are Drawing Investors’ Attention Today

Gold Resource Q4 EPS $(0.07) Misses $0.03 Estimate, Sales $29.03M Miss $29.44M Estimate

Why Is Pain & Liver Disease Focused DURECT Stock Plunging Today?

Coherus BioSciences Acquires Small Immuno-Oncology Player Surface Oncology For $40M